Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subject~* Age: 18 to 45 years (inclusive) at the first screening / examination visit~* Ethnicity: Caucasian~* Body mass index (BMI): \>/=18 and \</=29,9 kg/m²~Exclusion Criteria:~* Systolic blood pressure below 120 or above 145 mmHg~* Diastolic blood pressure above 95 mmHg~* Heart rate below 45 or above 95 beats / min~* Clinically relevant findings in the physical examination~* Suspicion of drug or alcohol abuse~* Regular daily consumption of more than 1 L of xanthin-containing beverages~* Intake of foods or beverages containing grapefruit within 4 weeks before the pre-study examination

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Nifedipine-candesartan FDC (Type: EXPERIMENTAL): Each subject received single fixed dose combination of 60 mg nifedipine and 32 mg candesartan orally.
- Nifedipine and candesartan (Type: ACTIVE_COMPARATOR): Each subject received one dose of nifedipine GITS 60 mg and candesartan 32 mg (2 x 16 mg tablet) as loose combination, orally.
- Nifedipine (Type: ACTIVE_COMPARATOR): Each subject received one dose of nifedipine GITS 60 mg orally.
- Candesartan (Type: ACTIVE_COMPARATOR): Each subject received one dose of candesartan 32 mg (2 x 16 mg tablet), orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).